Hypertension classification and latest guidance year 2025-2026
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have all the essential information. Let me compile a comprehensive, well-organized answer.
Hypertension Classification & Current Guidance (2025–2026)
1. Key Definitions
Blood pressure (BP) and cardiovascular (CV) risk have a continuous, linear relationship with no clear threshold — death from heart disease and stroke increases progressively from BP as low as 115/75 mmHg upward. All classification systems are therefore somewhat arbitrary, designed for clinical decision-making rather than reflecting a true biological cut-point. — Comprehensive Clinical Nephrology, 7th Ed.
2. ACC/AHA 2017 Classification (Current US Standard, Still in Use 2025–2026)
This remains the dominant US guideline framework and is used in the most recent editions of major textbooks (Harrison's 22nd Ed. 2025, Fuster & Hurst's The Heart 15th Ed.).
| Category | Systolic (mmHg) | Diastolic (mmHg) | |
|---|---|---|---|
| Normal | < 120 | and | < 80 |
| Elevated | 120–129 | and | < 80 |
| Hypertension Stage 1 | 130–139 | or | 80–89 |
| Hypertension Stage 2 | ≥ 140 | or | ≥ 90 |
| Hypertensive Crisis | > 180 | and/or | > 120 |
Also applies to children ≥13 years. Children aged 1–12 years use percentile-based thresholds (Stage 1: ≥95th percentile; Stage 2: ≥95th percentile + 12 mmHg or ≥140/90 mmHg).
— Fuster & Hurst's The Heart 15th Ed.; Lippincott Illustrated Reviews Pharmacology
Key shift from JNC 7: The old "prehypertension" (130–139/80–89) was reclassified as Stage 1 Hypertension, lowering the treatment threshold. This was controversial because it roughly doubled the number of Americans classified as hypertensive (~46% prevalence under ACC/AHA vs ~32% under JNC 7).
3. ESC/ESH 2018 Classification (Europe — Still Referenced in 2025 Guidelines)
| Category | Systolic (mmHg) | Diastolic (mmHg) | |
|---|---|---|---|
| Optimal | < 120 | and | < 80 |
| Normal | 120–129 | and/or | 80–84 |
| High Normal | 130–139 | and/or | 85–89 |
| Grade 1 Hypertension | 140–159 | and/or | 90–99 |
| Grade 2 Hypertension | 160–179 | and/or | 100–109 |
| Grade 3 Hypertension | ≥ 180 | and/or | ≥ 110 |
| Isolated Systolic HTN | ≥ 140 | and | < 90 |
Diagnostic thresholds (office BP): ≥140/90 mmHg
Ambulatory BP thresholds: Daytime ≥135/85; Nighttime ≥120/70; 24-hour ≥130/80
Home BP threshold: ≥135/85 mmHg
Ambulatory BP thresholds: Daytime ≥135/85; Nighttime ≥120/70; 24-hour ≥130/80
Home BP threshold: ≥135/85 mmHg
The ESC/ESH 2024 guidelines (released 2024, active through 2025–2026) updated treatment targets but retained the same classification structure. They emphasize that Grade 1 HTN with high CV risk should be treated pharmacologically even without compelling indications.
— Comprehensive Clinical Nephrology, 7th Ed.
4. ISH 2020 Global Guidelines Classification
Used in lower/middle-income countries as a practical global standard:
| Category | Systolic (mmHg) | Diastolic (mmHg) | |
|---|---|---|---|
| Normal BP | < 130 | and | < 85 |
| High Normal | 130–139 | and/or | 85–89 |
| Grade 1 Hypertension | 140–159 | and/or | 90–99 |
| Grade 2 Hypertension | ≥ 160 | and/or | ≥ 100 |
Diagnostic threshold (office BP): ≥ 140/90 mmHg
Home BP threshold: ≥ 135/85 mmHg
Home BP threshold: ≥ 135/85 mmHg
— Comprehensive Clinical Nephrology, 7th Ed.
5. Comparison Across Major Guidelines
| Feature | ACC/AHA 2017 | ESC/ESH 2018/2024 | ISH 2020 |
|---|---|---|---|
| HTN diagnosis threshold | ≥130/80 | ≥140/90 | ≥140/90 |
| "Normal" upper limit | <120/80 | <120/80 | <130/85 |
| Staging system | Stage 1 & 2 | Grades 1, 2, 3 | Grades 1 & 2 |
| "Prehypertension" concept | Replaced by "Elevated" | "High Normal" | "High Normal" |
| Isolated systolic HTN | Not separately classified | Recognized | Not separately classified |
6. Special BP Patterns
- White-coat hypertension: Office BP ≥140/90 but ambulatory/home BP normal. Associated with intermediate CV risk between normotension and sustained hypertension.
- Masked hypertension: Normal office BP but elevated ambulatory/home BP. Carries similar CV risk to sustained hypertension.
- Isolated systolic hypertension (ISH): SBP ≥140 with DBP <90 mmHg. Predominant in adults >60 years due to arterial stiffening; prevalence increases sharply with age.
- Resistant hypertension: BP remains ≥130/80 (ACC/AHA) or ≥140/90 (ESC) despite use of ≥3 antihypertensive agents including a diuretic at optimal doses.
- Hypertensive urgency vs. emergency: Both have SBP >180 and/or DBP >120; an emergency involves acute target organ damage (encephalopathy, ACS, acute HF, aortic dissection, eclampsia).
— Fuster & Hurst's The Heart 15th Ed.
7. BP Treatment Goals (2025 Guidance)
| Population | Target |
|---|---|
| General adults (uncomplicated) | < 130/80 (ACC/AHA) or <140/90 (ESC, ISH) |
| High CV risk / DM / CKD | < 130/80 |
| SPRINT-eligible adults | SBP < 120 mmHg (intensive target) |
| Elderly (≥65–80 years) | SBP 130–139 (individualized) |
| Elderly (>80 years) | SBP < 150 mmHg (ESC); individualize |
SPRINT trial context: Intensive SBP target (<120 mmHg) reduced major CV events and mortality vs <140 mmHg target. However, SPRINT used automated, unattended BP measurement — equivalent to ~128 mmHg by routine clinic measurement — so the real-world target is approximately <130 mmHg by standard clinic BP. — Comprehensive Clinical Nephrology, 7th Ed.
8. Classification by Etiology
| Type | Description |
|---|---|
| Primary (Essential) HTN | ~90–95% of cases; multifactorial (genetics, salt sensitivity, RAAS, sympathetic activity, aging) |
| Secondary HTN | ~5–10%; identifiable cause (renal parenchymal disease, renovascular HTN, primary aldosteronism, OSA, pheochromocytoma, thyroid disorders, drugs) |
| Isolated systolic HTN | Common in elderly; arterial stiffness mechanism |
| Salt-sensitive HTN | BP varies >10 mmHg with dietary sodium changes; more common in Black patients, CKD |
9. Pulmonary Hypertension Classification (WSPH 2018, Revised 2022)
Separate from systemic hypertension, pulmonary HTN (PH) is diagnosed when mean pulmonary artery pressure (mPAP) > 20 mmHg on right heart catheterization.
| Group | Etiology |
|---|---|
| Group 1 — PAH | Idiopathic, hereditary, drugs/toxins, CTD, HIV, portal HTN, congenital heart disease, schistosomiasis |
| Group 2 — Left heart disease | Mitral/aortic valve disease, LV systolic/diastolic dysfunction, HFpEF |
| Group 3 — Lung disease / hypoxia | COPD, ILD, sleep-disordered breathing |
| Group 4 — CTEPH | Chronic thromboembolic disease |
| Group 5 — Multifactorial/unclear | Sarcoidosis, metabolic disorders, chronic hemolytic anemia |
Hemodynamic subtypes:
- Isolated precapillary PH: mPAP >20 + PAWP ≤15 + PVR >2.0 WU
- Isolated postcapillary PH: mPAP >20 + PAWP >15 + PVR ≤2.0 WU
- Combined pre/postcapillary PH: mPAP >20 + PAWP >15 + PVR >2.0 WU
— Harrison's Principles of Internal Medicine 22nd Ed. (2025)
Summary: What's Current in 2025–2026
- The ACC/AHA 2017 framework (Stage 1 at ≥130/80) remains the US standard.
- The ESC/ESH 2024 guidelines (released August 2024) are the current European standard — retaining the Grade 1/2/3 structure but updating treatment algorithms with renewed emphasis on single-pill combination therapy early in management.
- ISH 2020 provides the pragmatic global standard, especially for resource-limited settings.
- No major new global classification revision has superseded these frameworks as of 2025–2026 — the differences between guidelines center on treatment thresholds and targets, not on the classification categories themselves.
- Ambulatory and home BP monitoring are increasingly emphasized for diagnosis confirmation and monitoring — out-of-office BP measurements are diagnostic in white-coat and masked hypertension.
This is a shared conversation. Sign in to Orris to start your own chat.